Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company specializing in complex rare disease treatments, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference in Miami Beach, FL.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company specializing in complex rare disease treatments, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference in Miami Beach, FL.
The company's management team will deliver a presentation on Monday, March 10, 2025, from 3:40 to 4:10 PM EST and engage in one-on-one investor meetings throughout the conference, which runs from March 10-12, 2025. The presentation will be accessible via webcast, and a replay will remain available for 30 days on Larimar's website under the 'Events and Presentations' section.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was +5.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.
Details on the presentation can be found below.
Date: Monday, March 10, 2025
Time: 3:40 – 4:10 PM EST
Webcast Link: https://wsw.com/webcast/leerink38/lrmr/2247553
Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.